DIAZEPAM | A210363 | REGCON HOLDINGS LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Lachman Consulting Services Inc FDA-2022-P-0118 · 6 docket documents Lachman Consulting Services Inc. filed a petition under section 505(j)(2)(c) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Diazepam Injection USP, 20 mg/4 mL (5 mg/mL) single dose prefilled syringe suitable for submission as an abbreviated new drug application (ANDA), w | Suitability | 2022-02-03 | Withdrawn | Lachman Consulting Services Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.